Eli Lilly Company News

Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit - CNBC

Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit CNBC

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company - investor.lilly.com

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company investor.lilly.com

Hims & Hers stock surges 7% on Eli Lilly partnership expansion - Investing.com

Hims & Hers stock surges 7% on Eli Lilly partnership expansion Investing.com

Full Range of FDA-Approved GLP-1s Available on Hims & Hers - Hims & Hers Newsroom

Full Range of FDA-Approved GLP-1s Available on Hims & Hers Hims & Hers Newsroom

Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride - statnews.com

Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride statnews.com

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) The Globe and Mail

Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects - Yahoo Finance

Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects Yahoo Finance

Eli Lilly can proceed with lawsuit against telehealth seller of weight-loss drugs - Courthouse News

Eli Lilly can proceed with lawsuit against telehealth seller of weight-loss drugs Courthouse News

Exclusive | Eli Lilly Strikes Deal for Cancer Biotech - WSJ

Exclusive | Eli Lilly Strikes Deal for Cancer Biotech WSJ

Lilly exits Rigel alliance, adding to RIPK1 scrap heap - BioSpace

Lilly exits Rigel alliance, adding to RIPK1 scrap heap BioSpace

Parkland School Board members concerned a tax break for Eli Lilly would shortchange district - The Morning Call

Parkland School Board members concerned a tax break for Eli Lilly would shortchange district The Morning Call

Eli Lilly Acquires Kelonia Therapeutics | PharmExec - Pharmaceutical Executive

Eli Lilly Acquires Kelonia Therapeutics | PharmExec Pharmaceutical Executive

Money Matters: The Onion takes over InfoWars and Eli Lilly buys a new company - WKMG

Money Matters: The Onion takes over InfoWars and Eli Lilly buys a new company WKMG

Eli Lilly Ends Collaboration with Rigel Pharmaceuticals (LLY) - GuruFocus

Eli Lilly Ends Collaboration with Rigel Pharmaceuticals (LLY) GuruFocus

Lilly to Acquire Kelonia in US$7 Billion Oncology Expansion - Mexico Business News

Lilly to Acquire Kelonia in US$7 Billion Oncology Expansion Mexico Business News

Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall - TradingView

Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall TradingView

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion - CNBC

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion CNBC

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - investor.lilly.com

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions investor.lilly.com

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - investor.lilly.com

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance investor.lilly.com

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - investor.lilly.com

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes investor.lilly.com

Statement: America’s leading role in biopharmaceutical innovation | Eli Lilly and Company - investor.lilly.com

Statement: America’s leading role in biopharmaceutical innovation | Eli Lilly and Company investor.lilly.com

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans - investor.lilly.com

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans investor.lilly.com

Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill - Yahoo Finance

Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill Yahoo Finance

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility - investor.lilly.com

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility investor.lilly.com

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company - investor.lilly.com

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company investor.lilly.com

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI | Eli Lilly and Company - investor.lilly.com

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI | Eli Lilly and Company investor.lilly.com

Eli Lilly to acquire Boston biotech Kelonia Therapy in $7 billion deal - Boston.com

Eli Lilly to acquire Boston biotech Kelonia Therapy in $7 billion deal Boston.com

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance - investor.lilly.com

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance investor.lilly.com

Eli Lilly To Acquire Kelonia Therapeutics In $7B Gene Therapy Deal - InkFreeNews.com

Eli Lilly To Acquire Kelonia Therapeutics In $7B Gene Therapy Deal InkFreeNews.com

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - investor.lilly.com

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen investor.lilly.com

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company - investor.lilly.com

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company investor.lilly.com

Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company - investor.lilly.com

Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company investor.lilly.com

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - investor.lilly.com

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 investor.lilly.com

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company - investor.lilly.com

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company investor.lilly.com

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients - investor.lilly.com

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients investor.lilly.com

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas - investor.lilly.com

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas investor.lilly.com